Study sheds light on why some prostate tumors are resistant to treatment

Researchers identify gene program that causes extreme non-response in one-third of patients

3:52 PM

Author | Nicole Fawcett

yellow pills spilling out of bottle
Getty Images

A study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment.

Treatments such as enzalutamide, which is an androgen receptor pathway inhibitor, are standard of care for advanced prostate cancer.

While many patients have long term good response to the drugs, some will derive no benefit whatsoever.

These “extreme non-responder” patients die much more quickly from prostate cancer.

The study, published in npj Precision Oncology, looked at RNA sequencing data and clinical outcomes from several prostate cancer clinical trial datasets.

The researchers identified a gene program linked to ARPI extreme non-response.

Moreover, they discovered the chemotherapy docetaxel could be a good option earlier on in patients whose tumor harbors the ARPI extreme non-response program.

Docetaxel is approved for prostate cancer but typically given later in the course of treatment.

“We found significant differences in the gene expression program between prostate cancers that do exceptionally well vs. exceptionally poorly with ARPIs. Patients who have this extreme non-response program appear to get significant benefit from docetaxel, suggesting these patients may be good candidates for earlier docetaxel treatment,” said lead first author Anbarasu Kumaraswamy, Ph.D., an investigator in the Alumkal Lab at the Rogel Cancer Center.

The researchers also found that the kinase CDK2 regulates the extreme non-response program, and targeting CDK2 could block the program and reduce tumor growth in the laboratory samples that harbored the ARPI extreme non-response program.

The authors suggest exploring CDK2 inhibitors, currently in clinical trials in other cancer types, as a promising new direction in prostate cancers with the extreme ARPI non-responder program.

Additional authors: Ya-Mei Hu, Joel A. Yates, Chao Zhang, Eva Rodansky, Dhruv Khokhani, Diana Flores, Zhi Duan, Yi Zhang, Shaadi Tabatabaei, Rachel Slottke, Shangyuan Ye, Primo Lara, Adam Foye, Charles J. Ryan, David A. Quigley, Jiaoti Huang, Rahul Aggarwal, Robert E. Reiter, Max S. Wicha, Tomasz M. Beer, Matthew Rettig, Martin Gleave, Christopher P. Evans, Owen N. Witte, Joshua M. Stuart, George V. Thomas, Felix Y. Feng, Eric J. Small, Zheng Xia, Joshi J. Alumkal

Funding: for this work is from Stand Up to Cancer-Prostate Cancer Foundation; Prostate Cancer Foundation; National Cancer Institute grants R01 CA251245, R01 CA282005, R01 CA291986, P50 CA186786, P30CA046592; National Comprehensive Cancer Network/Astellas Pharma Global Development/Pfizer Inc; Joint Institute for Cancer Research; Allen Family; Smith Family; U.S. Department of Defense grant W81XWH2110539; National Institute of General Medical Sciences grant R01 GM147365; National Institutes of Health grant T90 DE030859

Paper cited: “Transcriptional profiling clarifies a program of enzalutamide extreme nonresponse in lethal prostate cancer,” npj Precision Oncology. DOI: 10.1038/s41698-025-01002-8 


More Articles About:

All Research Topics Cancer (Oncology) Rogel Cancer Center Prostate Cancer Cancer Research
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

In This Story

Joshi Alumkal

Joshi J Alumkal, MD

Professor

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Mother sits on a couch with a laptop on her lap while an elementary school age boy sits next to her playing on a tablet device.
Health Lab

New questionnaire aims to improve understanding of demand avoidance in children, teens

Pathological demand avoidance is a pattern of intense distress and avoidance of demands in children. A new questionnaire from University of Michigan researchers creates a structured way to assess these behaviors.
Blue round cells in three pictures showing how they change under stress.
Health Lab

Timing is of the essence for RNA during stress

Key determiners of which RNA can be read to make proteins is time. Previous thinking was that a cell under threat would quickly make these RNAs in the nucleus and immediately push them into the cytoplasm.
Blue and yellow illustration of DNA helix
Health Lab

New anti-cancer strategy shows promise in preclinical studies

New cancer therapeutic strategy rewires protein interactions to improve efficacy and reduce potential side effects.
Closeup of newborn baby, whose head is held by a blue medical gloved hand. Blue gloved hand also holds a stethoscope to baby's chest.
Health Lab

More babies with hypoplastic left heart syndrome surviving critical period between surgeries

Collaborative effort helped sustain improvements in survival for babies born with hypoplastic left heart syndrome (HLHS), a serious congenital heart condition that requires multiple surgeries.
Rachel Upjohn Building groundbreaking ceremony
News Release

How U-M helped bring depression out of the darkness

The history of the founding of the Eisenberg Family Depression Center at the University of Michigan, the nation's first center focused on research, community outreach and stigma reduction in depression and bipolar disorder.
Group of men smiling in a field
News Release

How have diagnostic and treatment decisions for prostate cancer changed in recent years?

An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer. The analysis by University of Michigan Rogel Cancer Center researchers, indicates a shift toward surveillance in response to concerns of overdiagnosis and overtreatment that have hindered screening in the recent past.